Circulation Journal
Online ISSN : 1347-4820
Print ISSN : 1346-9843
Clinical Investigation
Increased Serum Glycated Albumin Level is Associated With the Presence and Severity of Coronary Artery Disease in Type 2 Diabetic Patients
Li Jin PuLin LuWei Feng ShenQi ZhangRui Yan ZhangJian Sheng ZhangJian HuZheng Kun YangFeng Hua DingQiu Jin ChenJie ShenDan Hong FangSheng Lou
Author information

2007 Volume 71 Issue 7 Pages 1067-1073


Background Glycated albumin is the predominant circulating Amadori-type glycated protein in vivo and plays a major role in the development of diabetic vascular complications. The aim of this study was to assess the relationship between increased serum glycated albumin level and the presence and severity of coronary artery disease (CAD) in patients with type 2 diabetes mellitus (T2DM). Methods and Results In a total of 320 consecutive patients with T2DM, coronary angiography revealed normal coronary arteries in 83 patients (control group) and significant coronary stenosis (≥70% luminal diameter narrowing) in 237, of whom 51 patients had 1-vessel disease (Group I), 80 had 2-vessel disease (Group II), and 106 had 3-vessel disease (Group III). Serum glycated albumin, hemoglobin A1c (HbA1c) and tumor necrosis factor (TNF)-α levels, lipid profile, and renal function were measured. Logistic regression analysis was performed to determine the relative risk of serum glycated albumin level for the presence and severity of CAD. Multivariate stepwise linear regression analysis was done to identify independent determinants of the glycated albumin level. Serum glycated albumin (21.2±5.3% vs 19.4±4.3%, p=0.005) and TNF-α levels (123 ±115 pg/ml vs 65±59 pg/ml, p<0.001) were significantly higher in patients with CAD than in controls, but serum HbAlc level did not significantly differ between them (7.6±1.3% vs 7.4±1.2%, p=0.19). There was a significant difference in serum glycated albumin level between Groups I and III (19.5±3.3% vs 21.8±5.7%, p<0.001). The serum glycated albumin level correlated with the number of diseased arteries (Spearman r=0.205, p<0.001), and was closely related to serum levels on admission of glucose (r=0.495, p<0.001), TNF-α (r=0.123, p=0.028), blood urea nitrogen (r=0.167, p=0.004), triglycerides (r=0.129, p=0.021), and HbA1c (r=0.795, p<0.001). Multivariate analysis indicated that serum levels of glucose (p<0.0001), TNF-α (p=0.001), blood urea nitrogen (p=0.004) and triglycerides (p=0.035) were independent determinants for glycated albumin. Logistic regression analysis revealed that glycated albumin ≥19% (odds ratio (OR) 2.9, p<0.001) was an independent predictor for CAD and glycated albumin ≥21% (OR 2.3, p=0.032) for 3-vessel disease prediction. The area under the receiver-operating characteristic curve for glycated albumin (0.620, 95% confidence interval (CI) 0.548 to 0.691, p=0.001) was superior to that for HbA1c (0.543, 95% CI 0.473 to 0.613, p=0.243). Conclusions An increased serum level of glycated albumin is associated with the presence and severity of CAD, and may be useful in screening patients with T2DM. (Circ J 2007; 71: 1067 - 1073)

Information related to the author
Previous article Next article